Women have many unique health concerns — menstrual cycles, pregnancy, birth control, menopause — and many more. Female organs can be affected by cancer or infections. Womens' cancers include breast cancer, ovarian cancer, cervical cancer, endometrial cancer, and other typical "female" malignant diseases. Common vaginal infections include bacterial infections, yeast infections, and Trichomoniasis. Endometriosis is an often painful disorder in which endometrial tissue grows outside of the uterus.
OncoLab, together with its international collaborators is dedicated to providing rapid, accurate diagnostic solutions for the understanding of disease biology with a focus on the microbiome, immunology and oncology.
CSC IF Test
Detecting Rare Cells in blood and other body fluids can be a real challenge. OncoLab provides research tools that make hunting for rare circulating stromal cells (CSC), a simple diagnostic test. The detection of CSC creates avenues for the development of less invasive diagnostic tools and opens possibilities for further study of the origin and the course of endometriosis.
OncoLab's CSC test is based on fluorescent immunostaining of stromal cells after enrichment from blood samples. State-of-the-art biomarkers coupled with enhanced scanning optical systems powered by artificial intelligence enable convenient and efficient research of CSC.
The list of products comprises special blood collection tubes, tools and reagents for cell purification, proprietary immunofluorescent cocktails for staining (IF), tools and general use reagents for preparing cytology slides, microscope imaging, and image analysis.
|nPACTM CSC IF Kit||12 rxn||OL5080012||nor for in vitro diagnostic use|
|Blood Collection Kit CE-IVD||12 samples||OL6010112|
|CRC IF Materials Kit||12 samples||OL5090012||nor for in vitro diagnostic use|
nCycte DxTM Advanced Optical Scanner
incl. nAble® Software
|nor for in vitro diagnostic use|
In the pipeline
First WOMENS HEATH products are focused on preterm births and the vaginal microbiome. Patented technology allows for the rapid identification of imbalances in the vaginal microbiome.
Cancer-specific tests for circulating tumor cells are under development (e.g. for breast cancer, ovarian cancer and other malignant gynecological diseases).